The global seasonal influenza vaccines therapeutics market was valued at around US$ 7.2 Billion at the end of 2021. The market is projected to register a 9.0% CAGR and top a valuation of US$ 18.3 Billion by 2032.
Increasing vaccination counts, broader vaccination coverage, and expanding government support for immunization against seasonal influenza are anticipated to drive the market for seasonal influenza vaccine therapeutics.
The flu shot, often known as the influenza vaccination, is used to protect against the influenza virus. The three virus strains that make up an influenza vaccination are influenza type A with the H3N2 virus strain, influenza type A with the H1N1 virus strain, and influenza type B virus strain. The influenza virus is a contagious respiratory infection that can cause mild to severe sickness.
The illness' severity could result in hospitalization or even death. Age groups like old people, children, and those with particular medical conditions are more at risk of developing significant flu complications. As part of the best practice to prevent infection, getting vaccinated against this virus annually should become a habit.
| Attributes | Details |
|---|---|
| Seasonal Influenza Vaccines Therapeutics Market Value in 2021 | US$ 7.2 Billion |
| Seasonal Influenza Vaccines Therapeutics Market Value in 2032 | US$ 18.3 Billion |
| Seasonal Influenza Vaccines Therapeutics Market CAGR (2022 to 2032) | 9.0% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Governments from all across the world are taking steps to encourage the use of the influenza vaccine. They are also researching the adverse reactions to the particular vaccine. Additionally, it is predicted that these elements will drive sales of influenza vaccines. Additionally, the incorporation of the influenza vaccine and growing routine immunization programs in both developed and developing countries are projected to expand sales opportunities in the seasonal influenza vaccine therapeutics market.
Major healthcare organizations are devoting a significant amount of resources and time to the creation of vaccinations as forms of advanced therapy. For instance, Seqirus invested in self-amplifying mRNA's upcoming influenza vaccine technology in August 2021.
In a report released in September 2021 by the CDC, it was said that because seasonal influenza viruses are continually evolving, vaccinations must likewise change to keep up. The market for therapeutic seasonal influenza vaccine therapeutics is expanding as a result of this aspect.
The market for influenza vaccines in North America currently accounts for the largest share, and it is anticipated that this market will grow even more throughout the projected period. This is a result of increased public awareness of viral infections and treatment options, government funding for education campaigns, and scientific developments in the creation of new vaccinations.
Apart from North America, the European market is the second market leader due to a variety of factors including an aging population, an increase in the occurrence of the flu and other related illnesses, and a high need for new vaccine development in the area.
The Asia Pacific region is also expected to uplift the revenue of the seasonal influenza vaccine therapeutics market. Due to the rising prevalence and incidence of influenza in this region, increased government support and surveillance about the influenza vaccine, and increased investment in the region by top global market participants.
Principal Consultant
CSL Seqirus, Merck, GlaxoSmithKline, Pfizer, Novartis, Sanofi, AstraZeneca, Abbott, SINOVAC, and F. Hoffman-La Roche Ltd. are the major players in the market.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 9.0% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Billion, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segment Covered | Vaccine Type, Age Group, Route of Administration, Distribution Channel, Region |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Players | CSL Seqirus; Merck; GlaxoSmithKline; Pfizer; Novartis; Sanofi; AstraZeneca; Abbott; SINOVAC; F. Hoffman-La Roche Ltd. |
| Customization | Available Upon Request |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global seasonal influenza vaccines therapeutics market is anticipated to register a CAGR of 9.0% during the forecast period.
CSL Seqirus, Merck, GlaxoSmithKline, Pfizer, Novartis, Sanofi, AstraZeneca, Abbott, SINOVAC, and F. Hoffman-La Roche Ltd. among others are some prominent market players.
Explore Healthcare Insights
View Reports
Seasonal Influenza Vaccines Therapeutics Market
